Clinical trial · no report yet · Phase 3
OrigAMI-5
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
- NCT07276399 ↗
- Recruiting
- Janssen Research & Development, LLC
- 18 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 10 | |
| Podcasts | 4 | |
| X threads | 3 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Squamous Cell Carcinoma of Head and Neck
- Interventions
- Amivantamab; Pembrolizumab; Carboplatin; 5-Flurouracil; Cisplatin
- Arms
- Arm A: Pembrolizumab, Amivantamab, Carboplatin · Experimental
- Arm B: Pembrolizumab, 5-Flurouracil (5-FU), Carboplatin or Cisplatin · Active comparator
- Enrollment
- 500 (estimated)
- Primary outcomes
- Overall Survival (OS)
- Objective Response Rate (ORR) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)
- Sponsor
- Janssen Research & Development, LLC
- Start
- Dec 3, 2025
- Primary completion
- Jun 18, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT07276399 · updated Sep 25, 2026